Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

dexpramipexole

- PMLiVE

Second darapladib failure disappoints GSK

Drug unable to demonstrate effectiveness in acute coronary syndrome

- PMLiVE

Merck’s vintafolide fails ovarian cancer trial

Major blow for drug’s original developers Endocyte

- PMLiVE

GSK terminates lung cancer vaccine trial

Unable to identify patients who may benefit from MAGE-A3 immunotherapy

- PMLiVE

Lilly depression drug fails late-stage trials

Will not pursue edivoxetine as an add-on treatment for depression

- PMLiVE

Ariad tanks as Iclusig trial is halted on safety grounds

Shares fall after leukaemia patients develop blood clots

Bristol-Myers Squibb (BMS) building

BMS’ Yervoy fails prostate cancer trial

Unable to improve overall survival in phase III

- PMLiVE

Setback for GSK as melanoma vaccine misses targets

Cancer immunotherapy disappoints in phase III

- PMLiVE

Amgen drug misses endpoint in acute heart failure trial

Company pledges to pursue development of omecamtiv mecarbil in chronic heart failure

- PMLiVE

Teva halts development of Nuvigil in bipolar disorder

Shelves plan to expand use of sleep disorder therapy

Bristol-Myers Squibb (BMS) building

BMS drops antidepressant in phase IIb

Liafensine no better than Lilly’s Cymbalta

- PMLiVE

Vical’s cancer immunotherapy fails in late-stage trial

Allovectin no better than standard chemotherapy

- PMLiVE

Isis drops arthritis candidate

ISIS-CRP Rx disappoints in phase II

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links